Moderna Files 8-K: Shareholder Vote & Financials
Ticker: MRNA · Form: 8-K · Filed: 2024-05-09T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, filing, financials
Related Tickers: MRNA
TL;DR
Moderna filed an 8-K for shareholder votes and financials.
AI Summary
Moderna, Inc. filed an 8-K on May 9, 2024, reporting on events that occurred on May 6, 2024. The filing indicates that the company submitted matters to a vote of its security holders and included financial statements and exhibits. No specific financial figures or details of the vote were provided in the excerpt.
Why It Matters
This filing signals that Moderna is engaging in corporate governance activities, including submitting proposals for shareholder approval and providing updated financial information.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information about significant financial changes, legal issues, or strategic shifts that would inherently increase risk.
Key Players & Entities
- Moderna, Inc. (company) — Registrant
- 325 Binney Street (location) — Principal executive offices address
- Cambridge, MA (location) — Principal executive offices city and state
- 02142 (location) — Principal executive offices zip code
- May 6, 2024 (date) — Date of earliest event reported
- May 9, 2024 (date) — Date of report
FAQ
What specific matters were submitted to a vote of Moderna's security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific proposals are not detailed in the provided excerpt.
What financial statements and exhibits are included in this 8-K filing?
The filing states that financial statements and exhibits are included, but their content is not specified in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 6, 2024.
What is Moderna, Inc.'s principal executive office address?
Moderna, Inc.'s principal executive office is located at 325 Binney Street, Cambridge, MA 02142.
What is Moderna's fiscal year end?
Moderna's fiscal year ends on December 31st.
From the Filing
0001682852-24-000031.txt : 20240509 0001682852-24-000031.hdr.sgml : 20240509 20240508175833 ACCESSION NUMBER: 0001682852-24-000031 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240506 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 24927770 BUSINESS ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 8-K 1 mrna-20240506.htm 8-K mrna-20240506 0001682852 false 12/31 0001682852 2024-05-06 2024-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549    FORM  8-K    CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware   001-38753   81-3467528  (State or other jurisdiction of incorporation)    (Commission File Number)    (IRS Employer Identification No.)   325 Binney Street Cambridge , MA   02142 (Address of principal executive offices)   (Zip code) Registrant’s telephone number, including area code: ( 617 )  714-6500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company       ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐ Item 5.03    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.   As further described under Item 5.07 of this Current Report on Form 8-K (this “Form 8-K”), at the 2024 Annual Meeting (as defined below) of Moderna, Inc. (the “Company”), and upon the recommendation of the Board of Directors (the “Board”) of the Company, the Company’s stockholders approved (i) a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the